Bredt David 4
4 · Rapport Therapeutics, Inc. · Filed Jan 16, 2026
Insider Transaction Report
Form 4
Bredt David
Chief Scientific Officer
Transactions
- Sale
Common Stock
[F1][F2]2026-01-15$26.83/sh−8,300$222,652→ 395,775 total - Sale
Common Stock
[F1]2026-01-15$27.40/sh−200$5,480→ 395,575 total
Footnotes (2)
- [F1]These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.33 to $27.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Signature
/s/ Troy Ignelzi, Attorney-in-Fact|2026-01-16